EDVA · Endovia Health Sciences, Inc. · Metrics
$0.25
+0.01 (+2.13%)
At close · Sep 11
Going-concern doubt
— flagged Aug 19, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company’s ability to continue as a going concern for the next 12 months.”View the 10-Q filed Aug 19, 2026
Market Cap
$1.60M
Shares
6.41M
EDVA metrics
58 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$0.25
Market cap
$1.60M
Price action
20 metricsPrice change (1W)
-5.6%
Price change (30D)
-38.5%
Price change (3M)
-66.7%
Price change (6M)
-88.1%
Price change (YTD)
-91.0%
Price change (1Y)
-96.5%
Trailing year
Price change (5Y)
-99.9%
52-week high
$10.16
52-week low
$0.24
Change from 52-week high
-97.5%
Change from 52-week low
+2.1%
Annualized volatility
190.6%
Annualized volatility (3M)
—
Beta
2.8
RSI (14D)
34.9
Price vs SMA 50
-41.6%
Price vs SMA 200
-86.4%
Avg volume (3M)
4.83M
Relative volume
0.1
Average dollar volume
$2.82M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
6.41M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
49.8×
reciprocal yield 2.0%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-1,081.5%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
338.7×
reciprocal yield 0.3%
EV / revenue historical average (5Y)
440.1×
reciprocal yield 0.2%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2024-09-30
Profitability
9 metricsGross margin
79.0%
Operating margin
-19,415.6%
Trailing 12 months
Net margin
-34,537.0%
Gross profit (TTM)
$25,348
Operating profit (TTM)
−$14.01M
Net income (TTM)
−$17.28M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-93.8%
Year over year
Net income growth YoY
—
Revenue (TTM)
$32,090
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+545.3%
Year over year · more shares
Revenue CAGR (3Y)
-84.1%
Revenue CAGR (5Y)
-49.8%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-1,605.7%
Debt / equity
—
Current ratio
0.1
EBITDA (TTM)
−$13.50M
Free cash flow (TTM)
—
Quick ratio
0.1
Interest coverage
-5.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$242,702
Total assets
$1.08M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$5.48M
Capital expenditures (TTM)
$3,542
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
$9.72M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
18
13F filer change QoQ
+2
Institutional ownership
17.3%
Short interest
3 metricsShort interest
3.6%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
35 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged